Abrégé

The present invention relates to methods for classifying a sample as from a BRCA1-related tumour or from a sporadic tumour based on copy number analysis of a numbers of genomic locations. The invention further provides sets of nucleic acid probes, arrays and kits comprising these sets and arrays, for use in the diagnostic and/or prognostic methods of the invention for tumour classification.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention concerns multimeric proteinaceous molecules comprising at least two members that bind each other via a region of noncovalent interaction, wherein a first of the members comprises a conditionally reactive group that, when activated, cleaves a covalent bond within the first member. Cleavage of the covalent bond results in a reduction in the binding strength with which the at least two members bind to each other via the region of noncovalent interaction. The reduction in the binding strength can result in the separation of the members under mild conditions.

Classes IPC  ?

• C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

Mycobacteria such as M. tuberculosis and M. leprae are considered to be prototypical intracellular bacilli that have evolved strategies to enable growth in the intracellular phagosomes of the host cell. By contrast, we show that lysosomes rapidly fuse with the virulent M. tuberculosis and M. leprae- containing phagosomes of human monocyte-derived dendritic cells and macrophages. After 2 days, M. tuberculosis progressively translocate from phagolysosomes into the cytosol where they replicate. Cytosolic entry is also observed for M. leprae but not for the vaccine strain, M. bovis BCG, or killed mycobacteria, and is dependent upon secretion of the mycobacterial gene products CFP-IO and ESAT-6 of the RDl region. The present invention further provides means and methods for using these findings in therapeutic and immunogenic compositions.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C12N 1/20 - BactériesLeurs milieux de culture
• C12R 1/32 - Mycobacterium

Abrégé

Mycobacteria such as M. tuberculosis and M. leprae are considered to be prototypical intracellular bacilli that have evolved strategies to enable growth in the intracellular phagosomes of the host cell. By contrast, we show that lysosomes rapidly fuse with the virulent M. tuberculosis and M. leprae-containing phagosomes of human monocyte-derived dendritic cells and macrophages. After 2 days, M. tuberculosis progressively translocate from phagolysosomes into the cytosol where they replicate. Cytosolic entry is also observed for M. leprae but not for the vaccine strain, M. bovis BCG, or killed mycobacteria, and is dependent upon secretion of the mycobacterial gene products CFP-10 and ESAT-6 of the RD1 region. The present invention further provides means and methods for using these findings in therapeutic and immunogenic compositions.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C12N 1/20 - BactériesLeurs milieux de culture
• C12R 1/32 - Mycobacterium

Abrégé

Methods for modulating apoptosis and neurite outgrowth in cells by modulating levels of PtdIns(4,5)P2. Agents for such modulation, including agents which inhibit or activate type I and type II PIP kinases, and methods for identifying such agents. Methods for treating or preventing hyperproliferative disorders and neurodegenerative diseases using such agents.

Classes IPC  ?

• C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61P 35/00 - Agents anticancéreux
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The invention relates to the field of medicine, in particular to cancer, more specifically breast cancer, most specifically to a method to predict the local recurrence of breast cancer after breast conserving therapy. It has been demonstrated that a classification on basis of the similarity of the gene expression profile to the gene expression profile of (serum) activated fibroblasts is able to distinguish significantly in risk of local recurrence in breast cancer patients.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques